459
Participants
Start Date
October 31, 2015
Primary Completion Date
July 31, 2020
Study Completion Date
July 31, 2020
Pexastimogene Devacirepvec (Pexa Vec)
Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
Sorafenib
"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
Auckland City Hospital, Auckland
Hospital of The University of Pennsylvania, Philadelphia
Mercy Medical Center, Inc., Baltimore
University of Florida Shands Hospital, Gainesville
University of Alabama, Birmingham
University of Tennessee Medical Center, Knoxville
University of Louisville, Louisville
Ohio State University, Columbus
University of Minnesota, Minneapolis
Billings Clinic, Billings
University of Chicago, Chicago
Saint Louis University, St Louis
Washington University School of Medicine, St Louis
Kansas City Research Institute, Kansas City
University of Kansas Cancer Center, Kansas City
Tulane University Health Sciences Center, New Orleans
University of Texas Southwestern Medical Center, Dallas
Mayo Clinic Arizona, Scottsdale
UC Irvine Medical Center, Orange
Stanford University School of Medicine, Palo Alto
Benaroya Research Institute at Virginia Mason Hospital, Seattle
Morristown Medical Center, Morristown
St. Joseph's Hospital, Paterson
Rhode Island Hospital, Providence
Site No. 8409, Adelaide
Site No. 8412, Adelaide
Site No. 8403, Brisbane
Site No. 8401, Camperdown
Site No. 8407, Clayton
Site No. 8406, Concord
Site No. 8408, Fitzroy
Site No. 8405, Footscray
Site No. 8414, Heidelberg
Site No. 8411, Melbourne
Site No. 8402, Parkville
Site No. 8415, Perth
Site No. 8413, Sydney
Site 8829, Changchun
Site No. 8821, Changsha
Site 8811, Fuzhou
Site 8820, Fuzhou
Site No.8816, Guangdong
Site 8827, Guangzhou
Site No.8828, Guangzhou
Site 8832, Hangzhou
Site No. 8802, Harbin
Site 8805, Hefei
Site No. 8808, Hefei
Site No.8815, Hefei
Site No. 8801, Nanjing
Site 8833, Qingdao
Site 8806, Shanghai
Site 8822, Shanghai
Site 8831, Shanghai
Site No. 8823, Xi'an
Site No. 8825, Xi'an
Site No. 9013, Bondy
Site No. 9005, Bordeaux
Site No. 9003, Créteil
Site No. 9006, Lille
Site 9012, Montpellier
Site No. 9008, Nantes
Site No. 9010, Nice
Site No. 9007, Paris
Site No. 9014, Paris
Site No. 9011, Rennes
Site No. 9001, Strasbourg
Site No. 9002, Toulouse
Site No. 9009, Vandœuvre-lès-Nancy
Site No. 9111, Aachen
Site No. 9113, Bonn
Site No. 9109, Dresden
Site No. 9108, Frankfurt am Main
Site No. 9106, Hamburg
Site No 9105, Hannover
Site No. 9112, Heidelberg
Site No. 9101, Mainz
Site No. 9102, München
Site No. 9104, Tübingen
Site No. 9110, Ulm
Site No. 8601, Hong Kong
Site No. 9707, Afula
Site 9704, Haifa
Site No. 9702, Haifa
Site No. 9705, Jerusalem
Site No. 9703, Ramat Gan
Site No. 9706, Tel Aviv
Site No.9205, Modena
Site No. 9204, Napoli
Site No. 9201, Palermo
Site No. 9203, Parma
Site No. 8902, Christchurch
Site No. 9404, Coimbra
Site No. 9405, Coimbra
Site No. 9403, Lisbon
Site No. 9401, Porto
Site No. 9402, Porto
Site 8702, Singapore
Site 8703, Singapore
Site No. 8701, Singapore
Site No. 8208, Ansan
Site No. 8211, Bucheon-si
Site No. 8201, Busan
Site 8216, Daegu
Site No. 8207, Daegu
Site No. 8213, Daegu
Site No. 8220, Daegu
Site 8224, Goyang
Site No. 8221, Jinju
Site No. 8218, Pusan
Site No. 8222, Seongnam
Site No. 8219, Seongnam-si
Site No. 8202, Seoul
Site No. 8203, Seoul
Site No. 8205, Seoul
Site No. 8209, Seoul
Site No. 8212, Seoul
Site No. 8215, Seoul
Site No. 8223, Seoul
Site No. 8210, Suwon
Site No. 8217, Ulsan
Site No. 8305, Kaohsiung City
Site No. 8307, Linkou District
Site No. 8306, Taichung
Site No. 8302, Tainan City
Site No. 8301, Taipei
Site No. 8303, Taipei
Site No. 8502, Bangkok
Site No. 8505, Bangkok
Site No. 8503, Chiang Mai
Site No. 8507, Hat Yai
Site No. 8501, Khon Kaen
Site No. 8506, Phitsanulok
Site No. 9501, Birmingham
Site No. 9505, Guildford
Site No. 9503, Leeds
Site No. 9502, London
Site No. 9504, London
Site No. 9506, London
University of Alberta Hospital, Edmonton
Juravinski Cancer Centre, Hamilton
Sunnybrook Health Sciences Centre, Toronto
SillaJen, Inc.
INDUSTRY